Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLC

Leggi l'articolo originale


Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.

Lascia un commento